BD Completes Acquisition of TriPath Imaging

Expands Presence in Cancer Diagnostics Market

22-Dec-2006

BD (Becton, Dickinson and Company) announced the completion of its acquisition of TriPath Imaging. The acquisition was finalized in accordance with terms originally disclosed in an announcement issued by BD on September 8, 2006.

According to the company, this strategic acquisition aligns innovative new technologies with BD's existing business strategies and is a natural complement to ongoing internal research programs in its BD Diagnostics and BD Biosciences segments. These oncology management tools are intended to span cancer screening, diagnosis, prognosis and therapy monitoring, especially for cancers affecting women's health, including breast, cervical and ovarian.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.